Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial to Assess the Efficacy and Safety of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder

Next Previous
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial to Assess the Efficacy and Safety of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical

    • Most Recent Events

    • 22 Dec 2023 According to an Otsuka Pharmaceutical media release, based on results from this trial, the company has obtained approval in Japan for an additional indication for Rexulti (generic name: brexpiprazole) for the treatment of Major Depressive Disorder (Administration should be limited to patients who showed an inadequate response to existing antidepressant therapy).
    • 30 Jan 2023 According to an Otsuka Pharmaceutical media release, the company has filed an application in Japan for an additional indication for Rexulti (generic name: brexpiprazole) for the treatment of Major Depressive Disorder (Administration should be limited to patients who showed an inadequate response to existing antidepressant therapy).
    • 12 Sep 2022 According to an Otsuka Pharmaceutical media release, additional analysis of the trial results is planned to further interpret the efficacy and safety of brexpiprazole.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top